ClinicalTrials.gg
RecruitingNCT06856837Updated Dec 12, 2025

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

A Phase 2 interventional study of Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer, sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. Recruiting at 23 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies testing HMPL-013 in Colorectal Neoplasms — 33 open to participants now, 38 under way, 3 of them phase 3. HMPL-013 · Colorectal Neoplasms.

Planned enrollment
7th of 61
140 · median 52
Started
2025
with 10 others
Phase 2
42 of 61
23 open now
Primary completion
2029-12
later than 35 of 37 live
Registered
45th of 61
by date

Among the 61 studies testing HMPL-013 in Colorectal Neoplasms, this one is the 7th largest by planned enrollment, is one of 11 that started in 2025, is one of 42 in phase 2, reaches primary completion later than 35 of the 37 other live ones, and was the 45th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

33 of the 61 studies testing HMPL-013 in Colorectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 33 open studies →

About HMPL-013

HMPL-013: first FDA approval 2023 (FRUZAQLA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing HMPL-013 in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.

Read the detailed description

Participants eligible for this trial will be randomized 1:1 into one of the two arms (Arm A and Arm B) stratified by: I) -Previous anti-angiogenic therapy (yes vs. no), II) BRAF/RAS mutation status (wildtype vs. mutation) or III) History of liver metastases (never vs. prior but treated).

Patients in Arm A (experimental arm) will receive Fruquintinib (orally, 5 mg once a day, at day 1-21 of each 28-day cycle [Q4W]) plus Tislelizumab (i.v., 400 mg, at day 1 of each 42-day cycle [Q6W]).

Patients in Arm B (control arm) will receive Trifluridine/tipiracil (orally, 35 mg/m2 twice a day, day 1-5 and day 8-12 of each 28-day cycle [Q4W]) plus Bevacizumab (i.v., 5 mg/kg, at day 1 of each 14-day cycle [Q2W]).

The treatment will be performed until disease progression, unacceptable toxicity, patients' request, or end of protocol-defined treatment time (maximum of 15 months).

All patients will be followed up for a maximum of 18 months after last patient in or until death, withdrawal of consent or loss to follow-up, whatever occurs first.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient* provide signed form.
  2. Patient is ≥ 18 years at the time of given informed consent.
  3. Patient has been diagnosed with or cytologically proven microsatellite stable (MSS)/proficient mismatch repair (pMMR) adenocarcinoma of the colon or rectum, which is not amenable to potentially curative resection.
  4. Known RAS (KRAS or NRAS) and BRAF V600E mutational status. Note: These mutations are mutually exclusive. Therefore, if one of the factors is mutated, it is not required to determine the mutation status of the others, as they are then assumed to be wildtype.
  5. Patient without liver metastases (NLM) defined as subjects without active liver metastases at screening as determined on baseline imaging of the liver as performed by CT scan with contrast or MRI. Definitively treated liver metastases (which includes surgical resection, microwave or radiofrequency ablation, or stereotactic body radiation therapy, but not yttrium-90 or chemoembolization alone) that were treated at least 3 months prior to enrollment with no evidence of radiologic progression on subsequent imaging are considered to be non-active liver metastases.
  6. Patient received at least one line of previous treatment with a fluoropyrimidine, oxaliplatin, irinotecan, VEGF(R) and if indicated EGFR and/or BRAF inhibitors in the advanced setting, or the patient has been intolerable or ineligible to those treatments.
  7. Patient has an performance status ≤ 1.
  8. Patient has a > 16 weeks.
  9. Patient has adequate hematological, hepatic and renal function.

    1. Absolute number of neutrophils (ANC) ≥ 1.5 x 109/L
    2. ≥ 100 x 109/L
    3. Total ≤ 1.5 times the (ULN) (or \< 2 x ULN in case of prior liver involvement or Gilbert's disease)
    4. (SGOT) and ALT (SGPT) ≤ 2.5 x ULN, AP ≤ 5 x ULN
    5. Serum creatinine ≤ 1.5 x ULN or (measured by 24 h urine) ≥ 30 mL/min (i.e., if serum creatinine level is > 1.5 x ULN, then a 24-hour urine test must be performed to check the creatinine clearance to be determined).
    6. Urinary protein ≤2+ on dipstick or routine urinalysis (UA; if urine dipstick or routine analysis is ≥3+, a 24-hour urine collection for protein must demonstrate \<2000 mg of protein in 24 hours to allow participation in this protocol)
  10. Adequate coagulation function as defined by (INR) ≤ 1.5, and a partial thromboplastin time (PTT) ≤ 5 seconds above the ULN (unless receiving anticoagulation therapy).
  11. Female patients of or male patients in Arm B with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use methods that result in a failure rate of \<1% per year during the treatment period and for at least 6 months after the last trial treatment. Male patients in Arm B with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy. Female patients of child-bearing potential must have a negative pregnancy test within the last 7 days prior to the start of trial therapy.
  12. Patient is willing and able to comply with the protocol (including contraceptive measures) for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

    • There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the trial gender-independently.

Exclusion criteria

Exclusion Criteria:

  1. Patient has known allergic / hypersensitive reactions to at least one of the treatment components
  2. Patient had previous other than that under study within 3 years or concomitant malignancy, except: those with a 5-year overall survival rate of more than 90%, e.g. non-melanomatous skin cancer or adequately treated in situ cervical cancer
  3. Patient received previous treatment with Fruquintinib, trifluridine/tipiracil, regorafenib or an /anti-PD-L1 antibodies.
  4. Patient receives current treatment with any anti-cancer therapy, such as systemic immunotherapy, chemotherapy, or hormone therapy within ≤ 2 weeks prior to study treatment start.
  5. Patient receives simultaneous treatment with a different anti-cancer therapy other than that provided for in the trial (excluding palliative radiotherapy for symptom control).
  6. Patient has known untreated or symptomatic CNS or .
  7. Patient has impaired cardiac function or cardiac disease including unstable angina within 6 months before the first dose of study treatment, acute myocardial infarction \< 6 months prior to the first dose of study treatment, (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure > 160 mmHg or diastolic > 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring antiarrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or interval (QTc) ≥ 470.
  8. Patient has history of uncontrolled infection with human deficiency virus () or chronic infection with or C virus (HBV, ).
  9. Patient has evidence of bleeding diathesis.
  10. Patient has history of gastrointestinal perforation or fistulae in past 6 months or risk factors for perforation.
  11. Patient has grade 3-4 gastrointestinal bleeding within 3 months prior to first dose of trial therapy.
  12. Use of strong inducers or inhibitors of within 2 weeks (or 5 half-lives, whichever is longer) before the first dose of study drug (see Appendix 4 for examples).
  13. Patient had a major surgery within 2 weeks prior to first dose of trial therapy.
  14. Patient experienced severe, life-threatening, or recurrent (Grade 2 or higher) immune-mediated adverse events (AEs) or infusion-related reactions including those that led to permanent discontinuation while on treatment with immune-oncology agents.
  15. Patient received prior therapy: immunosuppressive doses of systemic medications of > 10 mg/day of prednisone or equivalent must be discontinued ≥ 2 weeks before the first dose of study treatment. Short courses of high dose and/or continuous low dose of prednisone (\< 10 mg/day) are permitted. In addition, inhaled, intranasal, intraocular, and/or joint injections of corticosteroids are allowed.
  16. Patient has active disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study.
  17. Patient has history of solid organ transplantation .
  18. Patient has history of thromboembolic events (including deep vein thrombosis and pulmonary embolism) within the past 6 months or history of stroke and/or within the last 12 months.
  19. Patients has evidence of any other serious concomitant or medical condition that, in the opinion of the investigator, presents a high risk of complications to the patient or reduces the likelihood of clinical effect.
  20. Female patient is pregnant or breast feeding or planning to become pregnant within and up to 6 months after end of treatment.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Arm A

    * Fruquintinib (orally, 5 mg once a day, at day 1-21 of each 28-day cycle \[Q4W\]) plus * Tislelizumab (i.v., 400 mg, at day 1 of each 42-day cycle \[Q6W\])

    Drug: Fruquintinib · Drug: Tislelizumab

  • Active comparator
    Arm B

    * Trifluridine/tipiracil (orally, 35 mg/m2 twice a day, day 1-5 and day 8-12 of each 28-day cycle \[Q4W\]) plus * Bevacizumab (i.v., 5 mg/kg, at day 1 of each 14-day cycle \[Q2W\])

    Drug: Trifluridine/tipiracil · Drug: Bevacizumab

Interventions

  • DrugHMPL-013Studies of HMPL-013HMPL-013 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3

    Also known as: Fruzaqla

  • humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)

    Also known as: Tevimbra

  • DrugTrifluridine/tipiracil

    trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor

    Also known as: Lonsurf

  • recombinant humanized anti-VEGF monoclonal antibody composed of human IgG1 framework regions and antigen-binding, complementarity-determining regions from a murine monoclonal antibody (muMAb VEGF A4.6.1)

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of Fruquintinib in combination with the PD-1 inhibitor Tislelizumab in MSS/pMMR metastatic colorectal cancer without liver metastases.

    Progression-free survival (PFS), defined as time from randomization until date of progression acc. to RECIST v1.1 or death due to any cause.

    Time frame: up to 54 month

Secondary outcomes

  1. Overall survival

    Overall survival (OS), defined as time from randomization until date of death due to any cause.

    Time frame: up to 54 month

  2. Objective response rate

    Objective response rate (ORR), defined as proportion of patients achieving complete or partial response (CR/PR) acc. to RECIST v1.1.

    Time frame: up to 54 month

  3. Disease control rate

    Disease control rate (DCR), defined as proportion of patients achieving CR, PR, or stable disease (SD) acc. to RECIST v1.1.

    Time frame: up to 54 month

  4. Duration of response

    Duration of response (DoR), defined as time from response initiation (when either CR or PR is first determined) to disease progression acc. to RECIST v1.1 or death due to any cause.

    Time frame: up to 54 month

  5. To evaluate the safety and tolerability of Fruquintinib in combination with the PD-1 inhibitor Tislelizumab in MSS/pMMR metastatic colorectal cancer without liver metastases.

    Assessment of safety of the treatment as determined by the incidence, nature, causality, frequency, timing, and severity of adverse events using NCI CTCAE v5.0.

    Time frame: up to 54 month

  6. To assess health-related quality of life (HRQoL) data of Fruquintinib in combination with the PD 1 inhibitor Tislelizumab in MSS/pMMR metastatic colorectal cancer without liver metastases.

    Assessment of HRQoL during treatment and follow-up using EORTC QLQ C30 and EQ-5D-5L questionnaires.

    Time frame: up to 54 month

Other outcomes

  1. Exploratory Translational Objectives

    To correlate analysis between selected blood (such as ctDNA, chemokines/cytokines and metabolites) and stool (microbiota composition and metabolites) parameters and clinical data as well as dietary information to identify molecular biomarkers predictive for tumor response and survival.

    Time frame: up to 54 month

07

Study locations

15 of 23 sites recruiting
  • Ordensklinikum Linz GmbH
    Linz, Austria
    Not yet recruiting
    • Bernhard Doleschal, Dr. · Contact
    • Bernhard Doleschal, Dr. · Principal investigator
  • SCRI CCCIT Ges.m.b.H.
    Salzburg, Austria
    Recruiting
    • Lukas Weiss, Prof. Dr. · Contact
    • Lukas Weiss, Prof. Dr. · Principal investigator
  • Noe LGA Gesundheit Thermenregion GmbH
    Wiener Neustadt, Austria
    Not yet recruiting
    • Birgit Grünberger, Prof. Dr. · Contact
    • Birgit Grünberger, Prof. Dr. · Principal investigator
  • Klinikum St. Marien Amberg
    Amberg, Germany
    Recruiting
    • Ludwig Fischer von Weikersthal, Dr. · Contact
  • HELIOS Klinikum Bad Saarow
    Bad Saarow, Germany
    Recruiting
    • Daniel Pink, MD · Contact
    • Daniel Pink, MD · Principal investigator
  • Charite Universitaetsmedizin Berlin KöR
    Berlin, Germany
    Recruiting
    • Arndt Stahler, PD Dr. · Contact
    • Arndt Stahler, PD Dr. · Principal investigator
  • HELIOS Emil von Behring Berlin
    Berlin, Germany
    Recruiting
    • Börge Arndt, Dr. · Contact
    • Börge Arndt, Dr. · Principal investigator
  • Katholisches Klinikum Bochum gGmbH
    Bochum, Germany
    Not yet recruiting
    • Anke Reinacher-Schick, Prof. Dr. · Contact
    • Anke Reinacher-Schick, Prof. Dr. · Principal investigator
  • Universitätsklinikum Düsseldorf Klinik für Gastroenterologie, Hepatologie und Infektiologie Gastroonkologische Studienzentrale
    Düsseldorf, 40225, Germany
    Not yet recruiting
    • Christoph Roderburg, Prof. Dr. · Contact
    • Christoph Roderburg, Prof. Dr. · Principal investigator
  • KEM | Klinik für Internistische Onkologie gGmbH
    Essen, 45136, Germany
    Recruiting
    • Christian Müller, Dr. · Contact
    • Christian Müller, Dr. · Principal investigator
  • Universitätsklinikum Essen
    Essen, 45147, Germany
    Not yet recruiting
    • Stefan Kasper, Prof. Dr. · Contact
    • Stefan Kasper, Prof. Dr. · Principal investigator
  • Goethe University Frankfurt
    Frankfurt, Germany
    Recruiting
    • Christine Koch, PD Dr. · Contact
    • Christine Koch, PD Dr. · Principal investigator
  • Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest
    Frankfurt am Main, 60488, Germany
    Recruiting
    • Thorsten Götze, Prof. · Contact
    • Thorsten Götze, Prof. · Principal investigator
  • Hamburg Hämatologisch-Onkologische Praxis Eppendorf-Facharztzentrum Eppendorf
    Hamburg, 20246, Germany
    Recruiting
    • Alexander Stein, Prof. Dr. · Contact
    • Alexander Stein, Prof. Dr. · Principal investigator
  • Asklepios Kliniken Hamburg GmbH
    Hamburg, Germany
    Not yet recruiting
    • Dirk Arnold, Prof. Dr. · Contact
    • Dirk Arnold, Prof. Dr. · Principal investigator
  • University Medical Center Hamburg-Eppendorf
    Hamburg, Germany
    Recruiting
    • Joseph Tintelnot, Dr. · Contact
    • Joseph Tintelnot, Dr. · Principal investigator
  • Marienhospital Herne
    Herne, Germany
    Recruiting
    • Amin Turki, PD Dr. · Contact
    • Amin Turki, PD Dr. · Principal investigator
  • Vincentius-Diakonissen-Kliniken gAG
    Karlsruhe, 76137, Germany
    Not yet recruiting
    • Alexander Kolov, Dr. · Contact
    • Alexander Kolov, Dr. · Principal investigator
  • Klinikum der Universität München AöR
    München, Germany
    Recruiting
    • Sabrina Opatz, Dr. · Contact
    • Sabrina Opatz, Dr. · Principal investigator
  • Klinikum rechts der Isar TU München
    München, Germany
    Recruiting
    • Sylvie Lorenzen, Prof. Dr. · Contact
    • Sylvie Lorenzen, Prof. Dr. · Principal investigator
  • Leopoldina Krankenhaus Schweinfurt
    Schweinfurt, Germany
    Recruiting
    • Stephan Kanzler, Prof. · Contact
    • Stephan Kanzler, Prof. · Principal investigator
  • Klinikum Mutterhaus der Borromäerinnen gGmbH
    Trier, Germany
    Not yet recruiting
    • Ameen Aslan, Dr. · Contact
    • Ameen Aslan, Dr. · Principal investigator
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
    Recruiting
    • Thomas Ettrich, Dr. · Contact
    • Thomas Ettrich, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 50 months is close to that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
Mar 4, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06856837
Lead sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Oct 27, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Dec 12, 2025

Study contacts

Alexander Stein, Prof. Dr.
Contact
stein@hope-hamburg.de
+494036035220
Martin Walker
Contact
walker.martin@ikf-khnw.de
+4969589978772
Salah-Eddin Al-Batran, Prof. Dr.
study director · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Alexander Stein, Prof. Dr.
principal investigator · Hämatologisch-Onkologische Praxis Eppendorf University Cancer Center Hamburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HMPL-013 · Tislelizumab

Start the discussion